DOI: 10.1158/2643-3249.lymphoma26-a035 ISSN: 2643-3230

Abstract A035: ER-associated retrotranslocation generates a cytosolic OSTM1 E3 ubiquitin ligase that targets PDE3B for degradation

Hassan Sajjad, Muhammad Usama Tariq, Jianliang Shen, Rongrong Li, Namratha Sheshadri, Brinda Vallat, Stephen K. Burley, Christian Hinrichs, Jun Wang, Y. Lynn Wang, Jean Vacher, Ping Xie, Wei-Xing Zong

Abstract

Osteoclastogenesis-associated transmembrane protein 1 (OSTM1) is an ER/lysosomal luminal glycoprotein essential for lysosomal homeostasis, and its loss-of-function causes autosomal recessive osteopetrosis. We recently identified OSTM1 as a tumor suppressor in B-cell lymphomas (BCL) by promoting proteasomal degradation of phosphodiesterase 3B (PDE3B), but how a luminal protein exerts E3 ubiquitin ligase activity has remained unresolved. Here, we show that OSTM1 undergoes endoplasmic reticulum (ER)-associated retrotranslocation to generate a non-glycosylated cytosolic species, which preferentially engages PDE3B and catalyzes its ubiquitination and proteasomal turnover. Functionally, while the non-glycosylated cytosolic pool of OSTM1 predominantly exists in primary hematological cells, OSTM1 loss leads to PDE3B accumulation, enhanced cAMP hydrolysis, and attenuation of the tumor-suppressive PKA/CREB signaling axis. Genetic or pharmacological inhibition of PDE3B limits tumor growth and sensitizes cells to PI3Kγ inhibition. These findings establish glycosylation-dependent subcellular localization OSTM1 as a key determinant of its E3 activity and tumor-suppressive function and reveal PDE3B signaling as a therapeutic vulnerability in B-cell lymphoma.

Citation Format:

Hassan Sajjad, Muhammad Usama Tariq, Jianliang Shen, Rongrong Li, Namratha Sheshadri, Brinda Vallat, Stephen K. Burley, Christian Hinrichs, Jun Wang, Y. Lynn Wang, Jean Vacher, Ping Xie, Wei-Xing Zong. ER-associated retrotranslocation generates a cytosolic OSTM1 E3 ubiquitin ligase that targets PDE3B for degradation [abstract]. In: Proceedings of the Fifth AACR International Meeting on Advances in Malignant Lymphoma: From Discovery to Clinical Impact; 2026 Jun 24-27; Philadelphia, PA. Philadelphia (PA): AACR; Blood Cancer Discov 2026;7(3_Suppl):Abstract nr A035.

More from our Archive